Update on the Management and Treatment of Hepatitis C Virus Infection
* PegIFN alfa-2a 180 mcg per week or alfa-2b 1.5 mcg/kg per week. RBV (in two divided doses) with food: <75 kg: 1,000 mg per day or = 75 kg: 1,200 mg per day; alternative weight-based RBV dosing: <65 kg: 800 mg per day, 65-85 kg: 1,000 mg per day, >85-105 kg: 1,200 mg per day, >105 kg: 1,400 mg per day. BOC 800 mg (four 200 mg capsules) orally every 8 h with food.
† A sensitive real-time quantitative HCV RNA assay with a lower limit of detection of <10-15 IU/ml should be used for decision-making to determine treatment duration with response-guided therapy (RGT).
** BOC was not studied in null responders; this population was excluded from the Phase 3 study of patients who had previously failed treatment. efficacy data and FDA labeling for this population is based solely on mathematical modeling.
*** Discontinuation of BOC at week 36 is supported by modeling, but was not directly studied in the clinical trials. Following a 4-week lead-in with PegIFN-RBV, the addition of BOC to Peg-RBV for 44 weeks achieved higher sustained virologic response (SVR) compared with 24 weeks in late responders (detectable HCV RNA at week 8) in the registration trials.
U.S. Department of Veterans Affairs | 810 Vermont Avenue, NW Washington DC 20420
Last updated August 26, 2016